BioVersys AG (BIOVz)
CBOE 
Summary
BioVersys AG (BIOVz) FAQ
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has BioVersys AG ever had a stock split?
BioVersys AG Profile
| - Industry | - Sector | Dr. Marc Gitzinger CEO | CBOE Exchange | CH0210362643 ISIN |
| Switzerland Country | 33 Employees | - Last Dividend | - Last Split | - IPO Date |
Overview
BioVersys AG is a clinical-stage biopharmaceutical company headquartered in Basel, Switzerland. The company is dedicated to the research and development of small molecules featuring novel mechanisms of action to effectively combat antimicrobial resistance (AMR). BioVersys primarily focuses on addressing serious life-threatening infections caused by multi-drug resistant (MDR) bacteria. These infections include nosocomial instances caused by Acinetobacter baumannii and Staphylococcus aureus, as well as tuberculosis and non-tuberculous mycobacterial (NTM) infections.
With a robust pipeline, BioVersys includes several lead candidates, showcasing its commitment to developing transformative therapies for urgent health challenges. Utilizing proprietary platforms such as TRIC and Ansamycin Chemistry, the company aims to restore antibiotic efficacy, inhibit virulence, and address critical unmet needs within the AMR landscape and microbiome modulation. The company’s efforts are further corroborated by the prioritization of their targets by the World Health Organization (WHO) and Centers for Disease Control and Prevention (CDC).
With a workforce of approximately 29 employees, BioVersys plays a pivotal role within the biotechnology sector, pushing the boundaries of innovative treatments against high-priority pathogens.
Products and Services
- BV100: This candidate is a novel mode-of-action therapy currently in Phase 2 clinical trials, specifically targeting hospital infections caused by Acinetobacter baumannii. BV100 represents BioVersys's innovative approach in addressing complex and difficult-to-treat infections.
- BV200: An anti-virulence agent aimed at combating the severe effects of Staphylococcus aureus infections. By focusing on inhibiting virulence factors, BV200 seeks to enhance the efficacy of existing antibiotics and improve patient outcomes.
- BV500 Series: This series is designed to address non-tuberculous mycobacterial (NTM) infections, providing targeted research and potential therapeutic options for infections that often pose significant treatment challenges.
- Alpibectir (formerly BVL-GSK098): Currently in Phase 2a collaboration with GlaxoSmithKline for tuberculosis treatment, Alpibectir is an innovative therapeutic candidate that aims to fulfill critical needs in tuberculosis management.
